US20040086463A1 - Nasal solution containing a broad spectrum microbicide and a method for its use - Google Patents
Nasal solution containing a broad spectrum microbicide and a method for its use Download PDFInfo
- Publication number
- US20040086463A1 US20040086463A1 US10/690,242 US69024203A US2004086463A1 US 20040086463 A1 US20040086463 A1 US 20040086463A1 US 69024203 A US69024203 A US 69024203A US 2004086463 A1 US2004086463 A1 US 2004086463A1
- Authority
- US
- United States
- Prior art keywords
- ppmw
- concentration
- solution
- zinc
- nasal spray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- the invention relates generally to an aqueous nasal solution for use in treatment of and also the prevention of infection by microbes (like a head cold, flu, or other infection) and generally includes a broad-spectrum microbicide specifically including aqueous chlorine or bromine, hypochlorite ion and/or chloride, bromide or iodide ion.
- aqueous sodium hypochlorite can be used by itself or with the addition of glycerin or glycol for the treatment and prevention of infection.
- the invention relates generally to aqueous solution which contains a broad spectrum microbicide which may be applied in nasal passages in the manner of a decongestant type nose spray.
- the spray is intended particularly for human use. It is to be applied in the event of known or suspected exposure of the individual to common cold virus, flu, or other infective microbial agents including for example, bacteria, rickettsia, viruses and even mold and fungus. It may also be applied when there is a pre-existing infection caused by the previously mentioned agents.
- the solution contains an active agent which is based on a chlorine or hypochlorite solution, or a solution of chlorine or hypochlorite plus a salt of chloride, bromide or iodide.
- the solution may contain a bromine solution, or a solution of bromine plus a salt of chloride, bromide or iodide such as sodium chloride, zinc chloride, sodium bromide, zinc bromide, sodium iodide or zinc iodide.
- a salt of chloride, bromide or iodide such as sodium chloride, zinc chloride, sodium bromide, zinc bromide, sodium iodide or zinc iodide.
- the chlorine, hypochlorite, bromine, chloride, bromide, and iodide may originally come from inorganic compounds or organic compounds, which are then dissolved in the water.
- the solution may contain glycerin or another moisturizing or wetting agent for the nasal mucosa since the halogens or halides may be dehydrating or drying.
- Zinc gluconate or a zinc halide such as zinc chloride, zinc bromide or zinc iodide may also be included to further render the nasal
- Cold viruses or other microbes are sometimes transmitted by aerosol such as by a water droplet that is dispersed by coughing or sneezing, or by personal contact including, for example, hand to hand contact where a handshake transfers the microbes from one person to another and then the contaminated hand is brought into the vicinity of the individual's nose. (As when touching the nose or scratching it or rubbing it.) It is generally believed that infective agents will grow and multiply in regions where they have the proper temperature, nutrients, and other conditions conducive to growth or multiplication such as in the nasal mucosa.
- an object of the present invention is to apply a broad-spectrum microbicide to the area where infective viruses may be transmitted or transported and would ordinarily multiply.
- the composition may act to kill the microbe, or to render it ineffective.
- the microbicide may act to slow diffusion into a cell by tagging it with a heavy ion. This slowing of diffusion may slow the microbe's multiplication and allow the body's natural defenses to catch up and eliminate the microbes.
- the nasal solution may dilute the attacking organism and wash it out away from the optimum area for growth so as to weaken the statistical probability of success of the infection.
- a medical agent to the area of entry, namely the nose, and specifically the inside of the nose, the nasal fossae and the sinus areas within the nose.
- This treatment can be remedial so as to inhibit an existing infection, or prophylactic so as to prevent spread into the respiratory system by affecting the microbe in the nose.
- it could be applied as soon as the person has determined he or she has “caught” a cold. It could also be applied after the person first begins to feel the initial symptoms of catching a cold, such as stuffiness or muscular aches or fever.
- One preferred embodiment of the invention is an aqueous solution of sodium hypochlorite with a halogen salt such as sodium chloride, sodium bromide, sodium iodide, zinc chloride, zinc bromide or zinc iodide. It may also include more than one of the aforementioned salts. In addition, it may also include zinc gluconate.
- a halogen salt such as sodium chloride, sodium bromide, sodium iodide, zinc chloride, zinc bromide or zinc iodide. It may also include more than one of the aforementioned salts. In addition, it may also include zinc gluconate.
- Another embodiment of the invention would be an aqueous solution of chlorine with a halogen salt such as sodium chloride, sodium bromide, sodium iodide, zinc chloride, zinc bromide or zinc iodide. It may also include more than one of the aforementioned salts. In addition, it may also include zinc gluconate.
- a halogen salt such as sodium chloride, sodium bromide, sodium iodide, zinc chloride, zinc bromide or zinc iodide. It may also include more than one of the aforementioned salts. In addition, it may also include zinc gluconate.
- Another preferred embodiment of the invention is an aqueous solution of bromine with a halogen salt, i.e. chloride, bromide or iodide.
- the salt may constitute a chloride, a bromide or iodide with a specific example being sodium bromide, or zinc bromide.
- Another embodiment of this invention is the use of organic compounds of chlorine, bromine or iodine, or organic compounds that are chlorides, bromides or iodides. These compounds are such that they decompose in solution or chemically react in order to provide the necessary halogen components for making the aqueous mixture that will be used to spray into the nose onto the nasal mucosa.
- the solutions can contain glycerin or some other additive to act as a moisturizer since the halogen species tend to have a dehydrating, drying effect on the nasal mucosa.
- the pH could be adjusted, if necessary, to match the pH of mucous membranes or to optimize the activity without being harmful to the nasal mucosa. It can be adjusted up or down using sodium hydroxide, chlorine, sodium hypochlorite, hydrogen chloride, bromine, or hydrogen bromide.
- an appropriate pH for the final solution would be from about pH 5.5 to about pH 8.5, and preferably from about pH 6 to pH 8 and more preferably from about pH 6.5 to pH 7.5.
- Sodium hypochlorite would be present in a concentration of about 0.5 ppmw to about 50,000 ppmw, and preferably from about 5 ppmw to about 5000 ppmw and more preferably from about 50 ppmw to 500 ppmw. It may also be potassium, calcium, or other hypochlorites.
- Sodium or potassium chloride would be present in a concentration of about 55 ppmw to 75,000 ppmw, and preferably from 250 ppmw to 50,000 ppmw and more preferably from about 2500 ppmw to 25,000 ppmw. This could also be magnesium or calcium chloride or other chlorides.
- Sodium or potassium bromide would be present in a concentration of about 0.7 ppmw to about 140,000 ppmw, more preferably from about 140 ppmw to about 55,000 ppmw, and more preferably from about 1,400 ppmw to about 28,000 ppmw. This could also be magnesium or calcium bromide or other bromides.
- Sodium or potassium iodide would be present in a concentration of about 0.1 ppmw to about 160,000 ppmw, more preferably from about 200 ppmw to about 80,000 ppmw, and more preferably from about 2,000 ppmw to about 40,000 ppmw. This could also be magnesium or calcium iodide or other iodides.
- Chlorine would be present at a concentration of about 0.4 ppmw to about 50,000 ppmw, more preferably from about 2 ppmw to about 5000 ppmw, and more preferably from about 10 ppmw to about 500 ppmw.
- Bromine would be present at a concentration of about 1 ppmw to about 75,000 ppmw, more preferably from about 4 ppmw to about 8,000 ppmw, and more preferably from about 20 ppmw to about 1000 ppmw.
- Zinc chloride would be present at a concentration of about 0.4 ppmw to about 50,000 ppmw, more preferably from about 40 ppmw to about 15,000 ppmw, and more preferably from about 400 ppmw to about 5,000 ppmw.
- Zinc bromide would be present at a concentration of about 0.7 ppmw to about 80,000 ppmw, more preferably from about 75 ppmw to about 33,000 ppmw, and more preferably from about 750 ppmw to about 10,000 ppmw.
- Zinc iodide would be present at a concentration of about 1 ppmw to about 120,000 ppmw, more preferably from about 100 ppmw to about 80,000 ppmw, and more preferably from about 1,000 ppmw to about 20,000 ppmw.
- Zinc gluconate would be present at a concentration of about 1.7 ppmw to about 60,000 ppmw, more preferably from about 17 ppmw to about 6,000 ppmw, and more preferably from about 170 ppmw to about 1800 ppmw.
- Glycerine would be present at a concentration of about 0.01 wt % to about 5 wt %, more preferably from about 0.04 wt % to about 2 wt %, and more preferably from about 0.1 wt % to about 1 wt %.
- Propylene glycol could be used as a substitute for glycerine.
- normal bleach which is a NaOCl (sodium hypochlorite) solution of strength 5.25%
- the bleach was chosen to avoid some of the new versions that are marketed that include “lemon freshening”, etc. in order to avoid potential side effects from those scenting chemicals.
- a small quantity of the bleach was diluted to 1 ⁇ 5th of its original strength by adding 8 drops of the bleach to 32 drops of water to make a total solution of 40 drops of which 8 represent the original bleach.
- a separate container was filled with 45 milliliters of water. 3 drops of the 1.05% bleach solution were added to the water. The solution was thoroughly mixed and put into a nasal spray bottle.
- the spray was administered by spraying 2 to 4 times briskly into the nose while inhaling slightly. This was repeated approximately every 4 hours as needed.
- the subject observed a reduction of the mucosa production, as well as a lessening of the irritation of the back of the nose and pharynx, including the tonsils and adenoids.
- the nose and sinuses continued to decongest with further application of the spray and other cold symptoms were reduced or alleviated.
- the spray was administered by spraying 2 to 4 times briskly into the nose while inhaling slightly. This was repeated approximately every 4 to 5 hours as needed. The subject observed a noticeable reduction of the mucosa production, as well as a lessening of the irritation of the back of the nose and pharynx. The nose and sinuses continued to decongest with further application of the spray and other cold symptoms were reduced or alleviated.
- An example solution could be mixed up for use by a 53 year-old male for the alleviation of head cold symptoms, including the typical nasal congestion.
- the applications would be started after about 2 days into the progress of the cold.
- the following represents a list in detail of the manner in which the solution would be made.
- the spray would be administered by spraying 2 to 4 times briskly into the nose while inhaling slightly. This would be repeated approximately every 4 to 5 hours as needed. It is expected that the subject would observe a noticeable reduction of the mucosa production, as well as a lessening of the irritation of the back of the nose and pharynx. It is also expected that the nose and sinuses would continue to decongest with further application of the spray and other cold symptoms would be reduced or alleviated.
- An example solution could be mixed up for use by a 53 year-old male for the alleviation of head cold symptoms, including the typical nasal congestion.
- the applications would be started after about 2 days into the progress of the cold.
- the following represents a list in detail of the manner in which the solution would be made.
- liquid bromine 99.5+% which is at present available from Aldrich Chemicals would be used to prepare a ⁇ 3% w/w aqueous solution, by mixing 1 drop of bromine with 99 drops of water. (Note that bromine has an approximate density of 3.11 g/ml at 20 degrees Centigrade.)
- a separate solution would be made up by dissolving 1 gram of NaCl (sodium chloride) crystals in 45 milliliters of water. Once the solute was thoroughly dissolved, then 1 drop of the ⁇ 3% bromine solution would be added. The solution would be thoroughly mixed. Finally, 3 drops of glycerine would be added to the solution. The solution would be thoroughly mixed and put into a nasal spray bottle.
- the spray would be administered by spraying 2 to 4 times briskly into the nose while inhaling slightly. This would be repeated approximately every 4 to 5 hours as needed. It is expected that the subject would observe a noticeable reduction of the mucosa production, as well as a lessening of the irritation of the back of the nose and pharynx. It is also expected that the nose and sinuses would continue to decongest with further application of the spray and other cold symptoms would be reduced or alleviated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides for a nasal spray which is an aqueous solution containing a broad spectrum microbicide which may be applied in nasal passages in the manner of a decongestant type nose spray in the event of known or suspected exposure of the individual to common cold virus, flu, or other infective microbial agents. The solution contains active agents which are based on a chlorine or hypochlorite solution, or a solution of chlorine or hypochlorite plus a salt of chloride, bromide or iodide. Alternatively, the solution may contain a bromine solution, or a solution of bromine plus a salt of chloride, bromide or iodide such as sodium chloride, zinc chloride, sodium bromide, zinc bromide, sodium iodide or zinc iodide. The chlorine, hypochlorite, bromine, chloride, bromide, and iodide may originally come from inorganic compounds or organic compounds, which are then dissolved in the water. Further, the solution may contain glycerin or another moisturizing or wetting agent for the nasal mucosa. Zinc gluconate or a zinc halide such as zinc chloride, zinc bromide or zinc iodide may also be included.
Description
- The invention relates generally to an aqueous nasal solution for use in treatment of and also the prevention of infection by microbes (like a head cold, flu, or other infection) and generally includes a broad-spectrum microbicide specifically including aqueous chlorine or bromine, hypochlorite ion and/or chloride, bromide or iodide ion. In a further embodiment, aqueous sodium hypochlorite can be used by itself or with the addition of glycerin or glycol for the treatment and prevention of infection.
- The invention relates generally to aqueous solution which contains a broad spectrum microbicide which may be applied in nasal passages in the manner of a decongestant type nose spray. The spray is intended particularly for human use. It is to be applied in the event of known or suspected exposure of the individual to common cold virus, flu, or other infective microbial agents including for example, bacteria, rickettsia, viruses and even mold and fungus. It may also be applied when there is a pre-existing infection caused by the previously mentioned agents. The solution contains an active agent which is based on a chlorine or hypochlorite solution, or a solution of chlorine or hypochlorite plus a salt of chloride, bromide or iodide. Alternatively, the solution may contain a bromine solution, or a solution of bromine plus a salt of chloride, bromide or iodide such as sodium chloride, zinc chloride, sodium bromide, zinc bromide, sodium iodide or zinc iodide. The chlorine, hypochlorite, bromine, chloride, bromide, and iodide may originally come from inorganic compounds or organic compounds, which are then dissolved in the water. Further, the solution may contain glycerin or another moisturizing or wetting agent for the nasal mucosa since the halogens or halides may be dehydrating or drying. Zinc gluconate or a zinc halide such as zinc chloride, zinc bromide or zinc iodide may also be included to further render the nasal mucosa more slippery and thus more difficult for invading microbes to colonize the area.
- Cold viruses or other microbes are sometimes transmitted by aerosol such as by a water droplet that is dispersed by coughing or sneezing, or by personal contact including, for example, hand to hand contact where a handshake transfers the microbes from one person to another and then the contaminated hand is brought into the vicinity of the individual's nose. (As when touching the nose or scratching it or rubbing it.) It is generally believed that infective agents will grow and multiply in regions where they have the proper temperature, nutrients, and other conditions conducive to growth or multiplication such as in the nasal mucosa. Thus, an object of the present invention is to apply a broad-spectrum microbicide to the area where infective viruses may be transmitted or transported and would ordinarily multiply.
- A number of explanations could be proposed for the effectiveness of the microbicide in reducing the risk of full-blown infection. For example, the composition may act to kill the microbe, or to render it ineffective. Further, the microbicide may act to slow diffusion into a cell by tagging it with a heavy ion. This slowing of diffusion may slow the microbe's multiplication and allow the body's natural defenses to catch up and eliminate the microbes. Further, the nasal solution may dilute the attacking organism and wash it out away from the optimum area for growth so as to weaken the statistical probability of success of the infection.
- It is thus an object of the invention to apply a medical agent to the area of entry, namely the nose, and specifically the inside of the nose, the nasal fossae and the sinus areas within the nose. This treatment can be remedial so as to inhibit an existing infection, or prophylactic so as to prevent spread into the respiratory system by affecting the microbe in the nose. Thus, in accordance with a method of using the nasal spray, it could be applied as soon as the person has determined he or she has “caught” a cold. It could also be applied after the person first begins to feel the initial symptoms of catching a cold, such as stuffiness or muscular aches or fever. Or it could be applied prophylactically as soon as a person has been exposed to others who have colds and has real reason to be concerned about catching a cold after such an exposure. Moreover, it could be applied in a similar manner for cases of influenza or other infections for minimizing symptoms and extent of “infection”.
- One preferred embodiment of the invention is an aqueous solution of sodium hypochlorite with a halogen salt such as sodium chloride, sodium bromide, sodium iodide, zinc chloride, zinc bromide or zinc iodide. It may also include more than one of the aforementioned salts. In addition, it may also include zinc gluconate.
- Another embodiment of the invention would be an aqueous solution of chlorine with a halogen salt such as sodium chloride, sodium bromide, sodium iodide, zinc chloride, zinc bromide or zinc iodide. It may also include more than one of the aforementioned salts. In addition, it may also include zinc gluconate.
- Another preferred embodiment of the invention is an aqueous solution of bromine with a halogen salt, i.e. chloride, bromide or iodide. The salt may constitute a chloride, a bromide or iodide with a specific example being sodium bromide, or zinc bromide.
- Another embodiment of this invention is the use of organic compounds of chlorine, bromine or iodine, or organic compounds that are chlorides, bromides or iodides. These compounds are such that they decompose in solution or chemically react in order to provide the necessary halogen components for making the aqueous mixture that will be used to spray into the nose onto the nasal mucosa.
- There may be particular advantages of using mixed halogens since they sometimes combine in stable but reactive trimers like Br2Cl—, Br2I—, I2Cl—, I2Br—, etc. Having stabilized the reactive halogen, there will likely be more of the halogen present in the solution for reaction with sensitive areas of the microbes existing on the nasal mucosa.
- It is postulated that these ionic species will react chemically with organic or biological chemicals on or in the virus so as to kill it or render it ineffective. Further, the solutions can contain glycerin or some other additive to act as a moisturizer since the halogen species tend to have a dehydrating, drying effect on the nasal mucosa. The pH could be adjusted, if necessary, to match the pH of mucous membranes or to optimize the activity without being harmful to the nasal mucosa. It can be adjusted up or down using sodium hydroxide, chlorine, sodium hypochlorite, hydrogen chloride, bromine, or hydrogen bromide. Thus, an appropriate pH for the final solution would be from about pH 5.5 to about pH 8.5, and preferably from about pH 6 to pH 8 and more preferably from about pH 6.5 to pH 7.5.
- Sodium hypochlorite would be present in a concentration of about 0.5 ppmw to about 50,000 ppmw, and preferably from about 5 ppmw to about 5000 ppmw and more preferably from about 50 ppmw to 500 ppmw. It may also be potassium, calcium, or other hypochlorites.
- Sodium or potassium chloride would be present in a concentration of about 55 ppmw to 75,000 ppmw, and preferably from 250 ppmw to 50,000 ppmw and more preferably from about 2500 ppmw to 25,000 ppmw. This could also be magnesium or calcium chloride or other chlorides.
- Sodium or potassium bromide would be present in a concentration of about 0.7 ppmw to about 140,000 ppmw, more preferably from about 140 ppmw to about 55,000 ppmw, and more preferably from about 1,400 ppmw to about 28,000 ppmw. This could also be magnesium or calcium bromide or other bromides.
- Sodium or potassium iodide would be present in a concentration of about 0.1 ppmw to about 160,000 ppmw, more preferably from about 200 ppmw to about 80,000 ppmw, and more preferably from about 2,000 ppmw to about 40,000 ppmw. This could also be magnesium or calcium iodide or other iodides.
- Chlorine would be present at a concentration of about 0.4 ppmw to about 50,000 ppmw, more preferably from about 2 ppmw to about 5000 ppmw, and more preferably from about 10 ppmw to about 500 ppmw.
- Bromine would be present at a concentration of about 1 ppmw to about 75,000 ppmw, more preferably from about 4 ppmw to about 8,000 ppmw, and more preferably from about 20 ppmw to about 1000 ppmw.
- Zinc chloride would be present at a concentration of about 0.4 ppmw to about 50,000 ppmw, more preferably from about 40 ppmw to about 15,000 ppmw, and more preferably from about 400 ppmw to about 5,000 ppmw.
- Zinc bromide would be present at a concentration of about 0.7 ppmw to about 80,000 ppmw, more preferably from about 75 ppmw to about 33,000 ppmw, and more preferably from about 750 ppmw to about 10,000 ppmw.
- Zinc iodide would be present at a concentration of about 1 ppmw to about 120,000 ppmw, more preferably from about 100 ppmw to about 80,000 ppmw, and more preferably from about 1,000 ppmw to about 20,000 ppmw.
- Zinc gluconate would be present at a concentration of about 1.7 ppmw to about 60,000 ppmw, more preferably from about 17 ppmw to about 6,000 ppmw, and more preferably from about 170 ppmw to about 1800 ppmw.
- Glycerine would be present at a concentration of about 0.01 wt % to about 5 wt %, more preferably from about 0.04 wt % to about 2 wt %, and more preferably from about 0.1 wt % to about 1 wt %. Propylene glycol could be used as a substitute for glycerine.
- An example solution was mixed up and used by a 52 year-old male for the alleviation of head cold symptoms, including the typical nasal congestion. The applications were started early enough in the progress of the cold development that subsequent cold symptoms were relatively minor. It is not known to what extent the treatments altered the total course of the cold development, including its symptoms and extent. In order to provide a more concrete description of the example, the following represents a list in detail of the manner in which the solution was made.
- First of all, normal bleach, which is a NaOCl (sodium hypochlorite) solution of strength 5.25%, was obtained. The bleach was chosen to avoid some of the new versions that are marketed that include “lemon freshening”, etc. in order to avoid potential side effects from those scenting chemicals. A small quantity of the bleach was diluted to ⅕th of its original strength by adding 8 drops of the bleach to 32 drops of water to make a total solution of 40 drops of which 8 represent the original bleach. A separate container was filled with 45 milliliters of water. 3 drops of the 1.05% bleach solution were added to the water. The solution was thoroughly mixed and put into a nasal spray bottle.
- The spray was administered by spraying 2 to 4 times briskly into the nose while inhaling slightly. This was repeated approximately every 4 hours as needed. The subject observed a reduction of the mucosa production, as well as a lessening of the irritation of the back of the nose and pharynx, including the tonsils and adenoids. The nose and sinuses continued to decongest with further application of the spray and other cold symptoms were reduced or alleviated.
- An example solution was mixed up and used by a 52 year-old male for the alleviation of head cold symptoms, including the typical nasal congestion. The applications were started after a couple of days into the progress of the cold. It is not known to what extent the treatments altered the total course of the cold development, including its symptoms and extent. In order to provide a more concrete description of the example, the following represents a list in detail of the manner in which the solution was made.
- First of all, normal bleach, which is a NaOCl (sodium hypochlorite) solution of strength 5.25%, was obtained. The bleach-was chosen to avoid some of the new versions that are marketed that include “lemon freshening”, etc. in order to avoid potential side effects from those scenting chemicals. A small quantity of the bleach was diluted to ⅕th of its original strength by adding 8 drops of the bleach to 32 drops of water to make a total solution of 40 drops of which 8 represent the original bleach. 45 milliliters of water was placed into a separate container. Then 3 drops of the 1.05% bleach solution was added to the 45 milliliters of water. The solution was thoroughly mixed. Finally, 3 drops of glycerine were added to the solution. The solution was thoroughly mixed and put into a nasal spray bottle.
- The spray was administered by spraying 2 to 4 times briskly into the nose while inhaling slightly. This was repeated approximately every 4 to 5 hours as needed. The subject observed a noticeable reduction of the mucosa production, as well as a lessening of the irritation of the back of the nose and pharynx. The nose and sinuses continued to decongest with further application of the spray and other cold symptoms were reduced or alleviated.
- An example solution could be mixed up for use by a 53 year-old male for the alleviation of head cold symptoms, including the typical nasal congestion. The applications would be started after about 2 days into the progress of the cold. In order to provide a more concrete description of the example, the following represents a list in detail of the manner in which the solution would be made.
- First of all, normal bleach, which is a NaOCl (sodium hypochlorite) solution of strength 5.25%, would be obtained. The bleach would be chosen to avoid some of the new versions that are marketed that include “lemon freshening”, etc. in order to avoid potential side effects from those scenting chemicals. A small quantity of the bleach would be diluted to ⅕th of its original strength by adding 8 drops of the bleach to 32 drops of water to make a total solution of 40 drops of which 8 represent the original bleach. A separate solution would be made up by dissolving 0.5 gram of NaBr (sodium bromide) crystals in 45 milliliters of water. Once the solute was thoroughly dissolved, then 3 drops of the 1.05% bleach solution would be added. The solution would be thoroughly mixed. Finally, 3 drops of glycerine would be added to the solution. The solution would be thoroughly mixed and put into a nasal spray bottle.
- The spray would be administered by spraying 2 to 4 times briskly into the nose while inhaling slightly. This would be repeated approximately every 4 to 5 hours as needed. It is expected that the subject would observe a noticeable reduction of the mucosa production, as well as a lessening of the irritation of the back of the nose and pharynx. It is also expected that the nose and sinuses would continue to decongest with further application of the spray and other cold symptoms would be reduced or alleviated.
- An example solution could be mixed up for use by a 53 year-old male for the alleviation of head cold symptoms, including the typical nasal congestion. The applications would be started after about 2 days into the progress of the cold. In order to provide a more concrete description of the example, the following represents a list in detail of the manner in which the solution would be made.
- First of all, liquid bromine, 99.5+% which is at present available from Aldrich Chemicals would be used to prepare a ˜3% w/w aqueous solution, by mixing 1 drop of bromine with 99 drops of water. (Note that bromine has an approximate density of 3.11 g/ml at 20 degrees Centigrade.) A separate solution would be made up by dissolving 1 gram of NaCl (sodium chloride) crystals in 45 milliliters of water. Once the solute was thoroughly dissolved, then 1 drop of the ˜3% bromine solution would be added. The solution would be thoroughly mixed. Finally, 3 drops of glycerine would be added to the solution. The solution would be thoroughly mixed and put into a nasal spray bottle.
- The spray would be administered by spraying 2 to 4 times briskly into the nose while inhaling slightly. This would be repeated approximately every 4 to 5 hours as needed. It is expected that the subject would observe a noticeable reduction of the mucosa production, as well as a lessening of the irritation of the back of the nose and pharynx. It is also expected that the nose and sinuses would continue to decongest with further application of the spray and other cold symptoms would be reduced or alleviated.
- While in accordance with the patent statutes the best mode and preferred embodiment have been set forth, the scope of the invention is not limited thereto, but rather by the scope of the attached claims.
Claims (18)
1. A method of reducing the risk of microbial infection or of combating a microbial infection which is established first in the nasal mucosa area comprising:
the application of a nasal spray solution within the nose, said nasal spray solution comprising an aqueous solution having following components:
a) sodium hypochlorite in a concentration of about 0.5 ppmw to about 50,000 ppmw; and
optionally one or more of zinc gluconate at a concentration of about 1.7 ppmw to about 60,000 ppmw, and glycerine or propylene glycol at a concentration of about 0.01 wt % to about 5 wt %.
2. A method of reducing the risk of microbial infection or of combating a microbial infection which is established first in the nasal mucosa area comprising:
the application of a nasal spray solution within the nose, said nasal spray solution comprising an aqueous solution having following components:
a) chlorine in a concentration of about 0.4 ppmw to about 50,000 pp mw; and
optionally one or more of zinc gluconate at a concentration of about 1.7 ppmw to about. 60,000 ppmw, and glycerine or propylene glycol at a concentration of about 0.01 wt % to about 5 wt %.
3. A method of reducing the risk of microbial infection or of combating a microbial infection which is established first in the nasal mucosa area comprising:
the application of a nasal spray solution within the nose, said nasal spray solution comprising an aqueous solution having following components:
a) bromine in a concentration of about 1 ppmw to about 75,000 ppmw; and
optionally one or more of zinc gluconate at a concentration of about 1.7 ppmw to about 60,000 ppmw, and glycerine or propylene glycol at a concentration of about 0.01 wt % to about 5 wt %.
4. A method of reducing the risk of microbial infection or of combating a microbial infection which is established first in the nasal mucosa area comprising:
the application of a nasal spray solution within the nose, said nasal spray solution comprising an aqueous solution having following components:
a) sodium hypochlorite in a concentration of about 0.5 ppmw to about 50,000 ppmw;
b) from about 0.1 ppmw to 160,000 ppmw of a salt selected from one or more of sodium chloride and sodium bromide; and
optionally one or more of zinc gluconate at a concentration of about 1.7 ppmw to about 60,000 ppmw, and glycerine or propylene glycol at a concentration of about 0.01 wt % to about 5 wt %.
5. A method of reducing the risk of microbial infection and also of combating an established microbial infection which is established first in the nasal mucosa area comprising the application of a nasal spray solution within the nose, said nasal spray solution comprising an aqueous solution having;
a) from about 0.4 ppmw to about 50,000 ppmw of chlorine; and
b) from about 0.7 ppmw to 140,000 ppmw of a salt selected from one or more of sodium chloride or sodium bromide; and
optionally one or more of zinc gluconate at a concentration of about 1.7 ppmw to about 60,000 ppmw, and glycerine or propylene glycol at a concentration of about 0.01 wt % to about 5 wt %.
6. A method of reducing the risk of microbial infection and of combating a microbial infection which is established first in the nasal mucosa area comprising the application of a nasal spray solution within the nose, said nasal spray solution comprising an aqueous solution having one or more of the following components:
a) from about 1 ppmw to about 75,000 ppmw of bromine; and
b) from about 0.7 ppmw to 140,000 ppmw of a salt selected from one or more of sodium chloride or sodium bromide; and
optionally one or more of zinc gluconate at a concentration of about 1.7 ppmw to about 60,000 ppmw, and glycerine or propylene glycol at a concentration of about 0.01 wt % to about 5 wt %.
7. A nasal spray solution comprising an aqueous solution having following components:
a) bromine in a concentration of about 1 ppmw to about 75,000 ppmw; and
optionally one or more of zinc gluconate at a concentration of about 1.7 ppmw to about 60,000 ppmw, and glycerine or propylene glycol at a concentration of about 0.01 wt % to about 5 wt %.
8. The nasal spray solution as set forth in claim 7 wherein the bromine is present in a concentration of about 40 to about 8,000 ppmw.
9. The nasal spray solution as set forth in claim 8 wherein the bromine is present in a concentration of about 20 to about 1,000.
10. A nasal spray solution comprising an aqueous solution having following components:
a) sodium hypochlorite in a concentration of about 0.5 ppmw to about 50,000 ppmw;
b) from about 0.1 ppmw to 160,000 ppmw of a salt selected from one or more of sodium chloride and sodium bromide; and
optionally one or more of zinc gluconate at a concentration of about 1.7 ppmw to about 60,000 ppmw, and glycerine or propylene glycol at a concentration of about 0.01 wt % to about 5 wt %.
11. The nasal spray solution as set forth in claim 10 wherein component a) is present in a concentration of from about 5 to about 5,000 ppmw, and component b) is present in a concentration of about 140 to about 55,000 ppmw.
12. The nasal spray solution as set forth in claim 11 wherein component a) is present in a concentration of from about 50 to about 500 ppmw, and component b) is present in a concentration of about 1,400 to about 28,000 ppmw.
13. A nasal spray solution comprising an aqueous solution having the following components;
a) from about 0.4 ppmw to about 50,000 ppmw of chlorine; and
b) from about 0.7 ppmw to 140,000 ppmw of a salt selected from one or more of sodium chloride or sodium bromide; and
optionally one or more of zinc gluconate at a concentration of about 1.7 ppmw to about 60,000 ppmw, and glycerine or propylene glycol at a concentration of about 0.01 wt % to about 5 wt %.
14. The nasal spray solution as set forth in claim 13 wherein component a) is present in a concentration of from about 2 to about 5,000 ppmw, and component b) is present in a concentration of about 140 to about 55,000 ppmw.
15. The nasal spray solution as set forth in claim 14 wherein component a) is present in a concentration of from about 10 to about 500 ppmw, and component b) is present in a concentration of about 1,400 to about 28,000 ppmw.
16. A nasal spray solution comprising an aqueous solution having the following components:
a) from about 1 ppmw to about 75,000 ppmw of bromine; and
b) from about 0.7 ppmw to 140,000 ppmw of a salt selected from one or more of sodium chloride or sodium bromide; and
optionally one or more of zinc gluconate at a concentration of about 1.7 ppmw to about 60,000 ppmw, and glycerine or propylene glycol at a concentration of about 0.01 wt % to about 5 wt %.
17. The nasal spray solution as set forth in claim 16 wherein component a) is present in a concentration of from about 40 to about 8,000 ppmw, and component b) is present in a concentration of about 140 to about 55,000 ppmw.
18. The nasal spray solution as set forth in claim 17 wherein component a) is present in a concentration of from about 20 to about 1,000 ppmw, and component b) is present in a concentration of about 1,400 to about 28,000 ppmw.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/690,242 US20040086463A1 (en) | 2002-05-06 | 2003-10-21 | Nasal solution containing a broad spectrum microbicide and a method for its use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/139,522 US6664289B2 (en) | 2002-03-18 | 2002-05-06 | Nasal solution containing a broad spectrum microbicide and a method for its use |
US10/690,242 US20040086463A1 (en) | 2002-05-06 | 2003-10-21 | Nasal solution containing a broad spectrum microbicide and a method for its use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/139,522 Continuation-In-Part US6664289B2 (en) | 2002-03-18 | 2002-05-06 | Nasal solution containing a broad spectrum microbicide and a method for its use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040086463A1 true US20040086463A1 (en) | 2004-05-06 |
Family
ID=32174135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/690,242 Abandoned US20040086463A1 (en) | 2002-05-06 | 2003-10-21 | Nasal solution containing a broad spectrum microbicide and a method for its use |
Country Status (1)
Country | Link |
---|---|
US (1) | US20040086463A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8114343B1 (en) * | 2010-12-21 | 2012-02-14 | Ecolab USA, Inc. | Corrosion inhibition of hypochlorite solutions using Zn and Ca |
US20120241679A1 (en) * | 2010-12-21 | 2012-09-27 | Ecolab Usa Inc. | Corrosion inhibition of hypochlorite solutions |
US8557178B2 (en) | 2010-12-21 | 2013-10-15 | Ecolab Usa Inc. | Corrosion inhibition of hypochlorite solutions in saturated wipes |
US8603392B2 (en) | 2010-12-21 | 2013-12-10 | Ecolab Usa Inc. | Electrolyzed water system |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1802662A (en) * | 1925-06-15 | 1931-04-28 | Ralph H Mckee | Method of administering chlorine gas for the treatment of colds and the like |
US2739922A (en) * | 1952-03-13 | 1956-03-27 | Herman A Shelanski | Mixtures of polymeric n-vinyl pyrrolidone and halogens |
US3028300A (en) * | 1960-09-13 | 1962-04-03 | West Laboratories Inc | Germicidal compositions and methods for preparing the same |
US4197318A (en) * | 1974-07-08 | 1980-04-08 | Johnson & Johnson | Potentiated antimicrobial medicaments |
US4321257A (en) * | 1974-07-08 | 1982-03-23 | Johnson & Johnson | Potentiated medicaments |
US4355021A (en) * | 1980-10-29 | 1982-10-19 | S. C. Johnson & Son, Inc. | Virucidal wipe and method |
US4401651A (en) * | 1979-04-18 | 1983-08-30 | Knutson Richard A | Wound-healing compositions containing povidone-iodine |
US4474748A (en) * | 1979-09-26 | 1984-10-02 | Johnson & Johnson | Medicaments potentiated with phenyl alkanols |
US4985234A (en) * | 1988-05-20 | 1991-01-15 | Sunstar Kabushiki Kaisha | Iodine microbicide composite |
US5051256A (en) * | 1988-02-16 | 1991-09-24 | Barnes Carl E | Biocidal complex and dressing formed therefrom |
US5256701A (en) * | 1990-11-19 | 1993-10-26 | Zenzo Tamura | Disinfectant composition |
US5885620A (en) * | 1997-04-02 | 1999-03-23 | West Agro, Inc. | Stable glycerin iodine concentrate compositions |
US5897872A (en) * | 1997-11-12 | 1999-04-27 | Picciano; Dante J. | Iodine-containing nasal moisturizing saline solution |
US6156293A (en) * | 1997-01-03 | 2000-12-05 | Finnfedds Finland Ltd. | Moistening preparation |
US6664289B2 (en) * | 2002-03-18 | 2003-12-16 | Richard L. Hansen | Nasal solution containing a broad spectrum microbicide and a method for its use |
US6696041B2 (en) * | 2002-03-20 | 2004-02-24 | Richard L. Hansen | Treatment of colds, flu like infections and other general nasal based infections with a solution containing iodine and other broad spectrum microbicides and a method for its use |
US6809205B1 (en) * | 2000-01-18 | 2004-10-26 | Albemarle Corporation | Process for producing N-halogenated organic compounds |
-
2003
- 2003-10-21 US US10/690,242 patent/US20040086463A1/en not_active Abandoned
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1802662A (en) * | 1925-06-15 | 1931-04-28 | Ralph H Mckee | Method of administering chlorine gas for the treatment of colds and the like |
US2739922A (en) * | 1952-03-13 | 1956-03-27 | Herman A Shelanski | Mixtures of polymeric n-vinyl pyrrolidone and halogens |
US3028300A (en) * | 1960-09-13 | 1962-04-03 | West Laboratories Inc | Germicidal compositions and methods for preparing the same |
US4197318A (en) * | 1974-07-08 | 1980-04-08 | Johnson & Johnson | Potentiated antimicrobial medicaments |
US4321257A (en) * | 1974-07-08 | 1982-03-23 | Johnson & Johnson | Potentiated medicaments |
US4401651A (en) * | 1979-04-18 | 1983-08-30 | Knutson Richard A | Wound-healing compositions containing povidone-iodine |
US4474748A (en) * | 1979-09-26 | 1984-10-02 | Johnson & Johnson | Medicaments potentiated with phenyl alkanols |
US4355021A (en) * | 1980-10-29 | 1982-10-19 | S. C. Johnson & Son, Inc. | Virucidal wipe and method |
US5051256A (en) * | 1988-02-16 | 1991-09-24 | Barnes Carl E | Biocidal complex and dressing formed therefrom |
US4985234A (en) * | 1988-05-20 | 1991-01-15 | Sunstar Kabushiki Kaisha | Iodine microbicide composite |
US5256701A (en) * | 1990-11-19 | 1993-10-26 | Zenzo Tamura | Disinfectant composition |
US6156293A (en) * | 1997-01-03 | 2000-12-05 | Finnfedds Finland Ltd. | Moistening preparation |
US5885620A (en) * | 1997-04-02 | 1999-03-23 | West Agro, Inc. | Stable glycerin iodine concentrate compositions |
US5897872A (en) * | 1997-11-12 | 1999-04-27 | Picciano; Dante J. | Iodine-containing nasal moisturizing saline solution |
US6809205B1 (en) * | 2000-01-18 | 2004-10-26 | Albemarle Corporation | Process for producing N-halogenated organic compounds |
US6664289B2 (en) * | 2002-03-18 | 2003-12-16 | Richard L. Hansen | Nasal solution containing a broad spectrum microbicide and a method for its use |
US6696041B2 (en) * | 2002-03-20 | 2004-02-24 | Richard L. Hansen | Treatment of colds, flu like infections and other general nasal based infections with a solution containing iodine and other broad spectrum microbicides and a method for its use |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8114343B1 (en) * | 2010-12-21 | 2012-02-14 | Ecolab USA, Inc. | Corrosion inhibition of hypochlorite solutions using Zn and Ca |
US20120241679A1 (en) * | 2010-12-21 | 2012-09-27 | Ecolab Usa Inc. | Corrosion inhibition of hypochlorite solutions |
US8496853B2 (en) * | 2010-12-21 | 2013-07-30 | Ecolab Usa Inc. | Corrosion inhibition of hypochlorite solutions |
US8557178B2 (en) | 2010-12-21 | 2013-10-15 | Ecolab Usa Inc. | Corrosion inhibition of hypochlorite solutions in saturated wipes |
US8603392B2 (en) | 2010-12-21 | 2013-12-10 | Ecolab Usa Inc. | Electrolyzed water system |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6696041B2 (en) | Treatment of colds, flu like infections and other general nasal based infections with a solution containing iodine and other broad spectrum microbicides and a method for its use | |
US6664289B2 (en) | Nasal solution containing a broad spectrum microbicide and a method for its use | |
CN101189017B (en) | Method of using oxidative reductive potential water solution in dental applications | |
CN1845877B (en) | Oxidative reductive potential water solution, processes for producing same and methods of using the same | |
Smith | Fluoride toxicity | |
CN110799179A (en) | Solid composition comprising iodine reagent and sodium chloride with improved water solubility and antiviral and antibacterial composition for eye, oral cavity, nasal cavity or inhalation comprising aqueous solution thereof | |
MXPA05009960A (en) | Oxidative reductive potential water solution, processes for producing same and methods of using the same. | |
JP2009526029A (en) | (Metal-containing) virucidal composition and use | |
CN101820752A (en) | Method for controlling protozoa that harbor bacteria | |
US20110159462A1 (en) | Therapeutic agent for periodontal diseases and method of treating periodontal diseases | |
US10201563B2 (en) | Method of treating sinusitis, including chronic sinusitis | |
US20040086463A1 (en) | Nasal solution containing a broad spectrum microbicide and a method for its use | |
JP6955784B2 (en) | An antiviral and antibacterial composition for eyes, oral cavity, nasal cavity or inhalation containing a solid composition containing an iodo agent and sodium chloride having improved water solubility and an aqueous solution thereof. | |
JP5172678B2 (en) | Stabilized and preserved ketotifen-containing ophthalmic composition | |
CN109380277A (en) | A kind of disinfectant that can slowly permeate release | |
CN104586880A (en) | Preparation method of pure chlorine dioxide solution and method for treating Ebola virus infection | |
CN104434994A (en) | Mucocutaneous disinfectant | |
US20170100348A1 (en) | Treatment Regime for Chronic Sinusitis | |
US20020114850A1 (en) | Therapeutic bath solution containing alkali metal hypohalite | |
JPH11228387A (en) | Medicinal composition containing iodine-based antimicrobial agent | |
RU2165267C1 (en) | Method of combating aspergillosis when disinfecting cattle-breading rooms | |
US20200346957A1 (en) | Biofilm disruption leading to microbial destruction | |
CN114099567B (en) | Sterilizing and deodorizing spray for shoes and socks and preparation method thereof | |
JPH06172192A (en) | Aqueous disinfectant for vaginal and intraoral mucosa | |
TW202415390A (en) | Gel anti-itching material and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |